Cargando…

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade

INTRODUCTION: Chronic infections lead to the functional exhaustion of T cells. Exhausted T cells are phenotypically differentiated by the surface expression of the immunoinhibitory receptor, such as programmed death‐1 (PD‐1). The inhibitory signal is produced by the interaction between PD‐1 and its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganbaatar, Otgontuya, Konnai, Satoru, Okagawa, Tomohiro, Nojima, Yutaro, Maekawa, Naoya, Ichikawa, Yoshiki, Kobayashi, Atsushi, Shibahara, Tomoyuki, Yanagawa, Yojiro, Higuchi, Hidetoshi, Kato, Yukinari, Suzuki, Yasuhiko, Murata, Shiro, Ohashi, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589367/ https://www.ncbi.nlm.nih.gov/pubmed/34414683 http://dx.doi.org/10.1002/iid3.510

Ejemplares similares

Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies
por: WATARI, Kei, et al.
Publicado: (2021)

In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection
por: Nishimori, Asami, et al.
Publicado: (2017)

Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression
por: Sajiki, Yamato, et al.
Publicado: (2021)

Anti-Bovine Programmed Death-1 Rat–Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle
por: Okagawa, Tomohiro, et al.
Publicado: (2017)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves
por: Okagawa, Tomohiro, et al.
Publicado: (2023)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
por: Chandrasekaran, Deepika, et al.
Publicado: (2019)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
por: Chang, Katherine, et al.
Publicado: (2014)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing–remitting multiple sclerosis
por: Tsaktanis, Thanos, et al.
Publicado: (2023)

Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal
por: Fife, Brian T., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_s4fdd6a00i4dfiuc1a442pr481